Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.
Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, Garcia-Pavia P, Lakdawala NK, Nagueh SF, Rader F, Tower-Rader A, Turer AT, Coats C, Fifer MA, Owens A, Solomon SD, Watkins H, Barriales-Villa R, Kramer CM, Wong TC, Paige SL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham T; REDWOOD-HCM Steering Committee and Investigators. Maron MS, et al. J Am Coll Cardiol. 2023 Jan 3;81(1):34-45. doi: 10.1016/j.jacc.2022.10.020. J Am Coll Cardiol. 2023. PMID: 36599608 Free article. Clinical Trial.
Incidental finding of cornea verticillata or lamellar inclusions in kidney biopsy: measurement of lyso-Gb3 in plasma defines between Fabry disease and drug-induced phospholipidosis.
Politei J, Frabasil J, Durand C, Di Pietrantonio S, Fernandez A, Albertón V, Velasquez Rivas D, Barriales-Villa R, Larrañaga-Moreira J, Schenone AB. Politei J, et al. Biochim Biophys Acta Mol Basis Dis. 2021 Jan 1;1867(1):165985. doi: 10.1016/j.bbadis.2020.165985. Epub 2020 Oct 3. Biochim Biophys Acta Mol Basis Dis. 2021. PMID: 33022387 Free article.
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D; EXPLORER-HCM study investigators. Olivotto I, et al. Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29. Lancet. 2020. PMID: 32871100 Clinical Trial.
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Maurer MS, et al. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27. N Engl J Med. 2018. PMID: 30145929 Free article. Clinical Trial.
Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain.
de Frutos F, Ochoa JP, Gómez-González C, Reyes-Leiva D, Aróstegui JI, Casasnovas C, Barriales-Villa R, Sevilla T, Gonzalez-Lopez E, Ramil E, Galan L, González-Costello J, García-Álvarez A, Rojas-Garcia R, Espinosa MA, Garcia-Pavia P. de Frutos F, et al. Amyloid. 2023 Jun;30(2):199-207. doi: 10.1080/13506129.2022.2142110. Epub 2022 Nov 7. Amyloid. 2023. PMID: 36343383
Lamin A/C Ablation Restricted to Vascular Smooth Muscle Cells, Cardiomyocytes, and Cardiac Fibroblasts Causes Cardiac and Vascular Dysfunction.
Del Monte-Monge A, Ruiz-Polo de Lara Í, Gonzalo P, Espinós-Estévez C, González-Amor M, de la Fuente-Pérez M, Andrés-Manzano MJ, Fanjul V, Gimeno JR, Barriales-Villa R, Dorado B, Andrés V. Del Monte-Monge A, et al. Int J Mol Sci. 2023 Jul 6;24(13):11172. doi: 10.3390/ijms241311172. Int J Mol Sci. 2023. PMID: 37446344 Free PMC article.
Diagnosis of transthyretin amyloidosis in patients with established cardiomyopathy.
Martín-Álvarez E, Larrañaga-Moreira JM, Barge-Caballero G, Souto-Caínzos B, Crepo-Leiro MG, Barriales-Villa R. Martín-Álvarez E, et al. Among authors: barriales villa r. Rev Esp Cardiol (Engl Ed). 2024 Apr;77(4):347-349. doi: 10.1016/j.rec.2023.09.012. Epub 2023 Dec 1. Rev Esp Cardiol (Engl Ed). 2024. PMID: 38043734 English, Spanish. No abstract available.
Impact of SARS-CoV-2 infection in patients with cardiac amyloidosis: Results of a multicentre registry.
Larrañaga-Moreira JM, Rodriguez-Serrano AI, Domínguez F, Lalario A, Zorio E, Barriales-Villa R; Dilemma International Cardiomyopathy, Heart Failure Registry Investigators Group. Larrañaga-Moreira JM, et al. Among authors: barriales villa r. Med Clin (Barc). 2023 Dec 7;161(11):476-482. doi: 10.1016/j.medcli.2023.06.025. Epub 2023 Sep 6. Med Clin (Barc). 2023. PMID: 37684159 English, Spanish.
Diagnosing transthyretin amyloidosis in patients with known genetic cardiomyopathies - opportunities and open questions. Response.
Martín-Álvarez E, Larrañaga-Moreira JM, Crepo-Leiro MG, Barriales-Villa R. Martín-Álvarez E, et al. Among authors: barriales villa r. Rev Esp Cardiol (Engl Ed). 2024 Jan 16:S1885-5857(24)00025-2. doi: 10.1016/j.rec.2023.12.009. Online ahead of print. Rev Esp Cardiol (Engl Ed). 2024. PMID: 38237660 English, Spanish. No abstract available.
127 results